deltatrials
Completed PHASE1 INTERVENTIONAL NCT00102297

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Sponsor: Kyntra Bio

Conditions Diabetes Mellitus
Interventions FG-3019
Updated 6 times since 2017 Last updated: Dec 10, 2007 Started: Jan 31, 2005 Completion: Jun 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetes Mellitus and is currently completed. Kyntra Bio leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshotCompleted~Feb 2026 – present · 5 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Feb 2026 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kyntra Bio
Data source: Kyntra Bio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations